Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Operating Leases (2021 - 2024)

Valion Bio has reported Operating Leases over the past 4 years, most recently at $141000.0 for Q1 2024.

  • For Q1 2024, Operating Leases fell 72.08% year-over-year to $141000.0; the TTM value through Mar 2024 reached $141000.0, down 72.08%, while the annual FY2023 figure was $176000.0, 52.04% down from the prior year.
  • Operating Leases for Q1 2024 was $141000.0 at Valion Bio, down from $176000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $573000.0 in Q3 2022 and troughed at $141000.0 in Q1 2024.
  • A 4-year average of $397400.0 and a median of $460500.0 in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: grew 0.2% in 2023 and later plummeted 72.08% in 2024.
  • Year by year, Operating Leases stood at $545000.0 in 2021, then crashed by 32.66% to $367000.0 in 2022, then plummeted by 52.04% to $176000.0 in 2023, then dropped by 19.89% to $141000.0 in 2024.
  • Business Quant data shows Operating Leases for TIVC at $141000.0 in Q1 2024, $176000.0 in Q4 2023, and $242000.0 in Q3 2023.